2. UroToday Home
  3. Categories

Prostate Cancer

The Predictive Role of [177Lu]Lu-PSMA-617 SPECT/CT Semiquantitative Parameters from the 1st RLT Cycle in Advanced mCRPC: A Preliminary Bicentric Lesion-Based Analysis - Beyond the Abstract

Details
[¹⁷⁷Lu]Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is an effective option for advanced metastatic castration-resistant prostate cancer (mCRPC).1 Thanks to the [177Lu]Lu-characteristics (~10% of γ-emission), it is possible to image the biodistribution of the RLT with single-photon emission computed tomography/computed tomography (SPECT/CT) starting from 4 hours after the injection at each RLT cycle.2

The Evolving PI-RADS Paradigm - Beyond the Abstract

Details
While PI-RADS v2.1 has successfully established multiparametric MRI (mpMRI) as the international standard for prostate cancer diagnosis, everyday clinical practice continues to highlight areas where the framework can be further refined to improve consistency, reproducibility, and patient-centered care.

External validation of the P-Score in the prospective, pre-biopsy DEPROMP cohort: integrated mpMRI and PSMA PET/CT risk stratification for prostate cancer detection.

Details

This study aimed to externally validate the P-Score, a composite scoring system combining PI-RADS and PRIMARY score, for its diagnostic accuracy in detecting clinically significant (ISUP ≥ 2) and higher-grade (ISUP ≥ 3) prostate cancer (PCa).

The psychosocial impact of receiving a polygenic risk score informing risk of prostate cancer.

Details

Use of polygenic risk scores (PRS) as a risk-stratification tool in cancer screening is an area of increasing interest. The BARCODE1 study is an observational prostate cancer screening study, investigating the use of PRS to risk-stratify people by risk of prostate cancer, with those identified as higher risk invited for prostate cancer screening.

Development of a Unified Framework for Evaluating the Quality of Physician Communication in Prostate Cancer Treatment Consultations.

Details

Physicians often fail to communicate important details about key risks and benefits of treatment in prostate cancer consultations, an information gap that may inhibit effective patient participation in care decisions.

The utility of PSA density for selection of targeted versus systematic transperineal prostate biopsy: A retrospective cohort study.

Details

The objective of this study is to evaluate PSA density (PSAD) as an adjunctive predictor of prostate cancer (PCa) detection on magnetic resonance imaging (MRI)-guided transperineal biopsy and to identify PSAD thresholds across which systematic sampling may be safely omitted.

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.

Details

Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process.

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.

Details

Following completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process.

Abiraterone or Enzalutamide for Patients With Metastatic Castration-Sensitive Prostate Cancer: A Nationwide Veterans Affairs Study.

Details

Enzalutamide or abiraterone, combined with androgen-deprivation therapy, is standard of care for metastatic castration-sensitive prostate cancer (mCSPC). However, no trials have compared these drugs.

Same Target, Different Tools: A Multicenter Comparison of Local Anesthesia Cognitive Fusion, General Anesthesia Fusion, and General Anesthesia Grid Prostate Biopsy - Beyond the Abstract

Details
The debate over how best to perform MRI-targeted transperineal prostate biopsy (TPPB) has long centred on a single question: does cognitive fusion (CF) perform equivalently to software-assisted fusion (SAF)? Until now, the prevailing evidence suggested it did. Khoo et al. (2021),1 in a series of 1,071 patients comparing visual estimation with software-based image fusion using the Biopsy platform, found no significant difference in cancer detection rates between the two approaches. Hung et al. (2024) reached a similar conclusion across 409 patients and 11 operators. Our study builds on this foundation — but takes the analysis a critical step further.
Page 1 of 3288